This trial is active, not recruiting.

Condition achromatopsia
Sponsor Applied Genetic Technologies Corp
Collaborator National Eye Institute (NEI)
Start date June 2013
End date July 2017
Trial size 150 participants
Trial identifier NCT01846052, 1R24EY022023, ACHM-001


The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Visual acuity
time frame: Annually for up to 1.5 years

Secondary Outcomes

Color Vision
time frame: annually for up to 1.5 years
Adaptive Optics Retinal Imaging
time frame: annually for up to 1.5 years

Eligibility Criteria

All participants at least 6 years old.

Inclusion Criteria: 1. Clinical diagnosis of achromatopsia (screening portion of study); 2. Molecular confirmation of mutations in the CNGB3 gene (main portion of study); 3. At least 6 years of age; 4. Willing and able to perform study procedures; 5. Signed informed consent(s) obtained (and child assent where applicable). Exclusion Criteria: 1. Not able to have a blood sample drawn; 2. Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment); 3. Participating in an interventional research study of drugs or devices for treatment of achromatopsia or other retinal diseases; 4. Use of medications that may impair color vision (e.g. hydroxychloroquine); 5. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Additional Information

Official title Clinical and Genetic Characterization of Individuals With Achromatopsia
Description Individuals with a clinical diagnosis of achromatopsia will be asked to provide informed consent and will then have a single 5 mL blood sample drawn for DNA sequence analysis of genes known to cause achromatopsia, including the CNGB3 gene. All participants will be informed of the results of testing for these mutations. Those with mutations in both alleles of the CNGB3 gene will be evaluated every 6 months for up to 1.5 years by using a variety of non-invasive visual function tests to more fully characterize their clinical condition. This testing will include routine ophthalmic examination and tests of visual acuity, color vision, reading speed, perimetry, nystagmus, light sensitivity, optical coherence tomography, adaptive optics retinal imaging, electroretinography, fundus photography and completion of a quality of life questionnaire.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Applied Genetic Technologies Corp.